. The company’s pipeline contains four clinical-stage therapies. Its most advanced drug applicant is ROS1 inhibitor taletrectinib for managing lung cancer. Nuvation is completing two stage 2 pivotal reports on taletrectinib. Any rally that follows last week's Excessive minimal will then need to be judged for a way nicely https://financefeeds.com/copyright-eyes-1b-capital-raise-ahead-of-2026-ipo/